Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by Gabriel Virella and Maria Lopes-Virella.
Gabriel Virella
Connection Strength
8.110
Maria Lopes-Virella
  1. Modified LDL Immune Complexes and Cardiovascular Disease. Curr Med Chem. 2019; 26(9):1680-1692.
    View in: PubMed
    Score: 0.692
  2. Immune complexes containing malondialdehyde (MDA) LDL induce apoptosis in human macrophages. Clin Immunol. 2018 02; 187:1-9.
    View in: PubMed
    Score: 0.624
  3. The role of the immune system in the pathogenesis of diabetic complications. Front Endocrinol (Lausanne). 2014; 5:126.
    View in: PubMed
    Score: 0.509
  4. Pathogenic role of modified LDL antibodies and immune complexes in atherosclerosis. J Atheroscler Thromb. 2013; 20(10):743-54.
    View in: PubMed
    Score: 0.477
  5. Immunoassay of modified forms of human low density lipoprotein in isolated circulating immune complexes. J Immunoassay Immunochem. 2013; 34(1):61-74.
    View in: PubMed
    Score: 0.457
  6. The Pathogenic Role of the Adaptive Immune Response to Modified LDL in Diabetes. Front Endocrinol (Lausanne). 2012; 3:76.
    View in: PubMed
    Score: 0.440
  7. Clinical significance of the humoral immune response to modified LDL. Clin Immunol. 2010 Jan; 134(1):55-65.
    View in: PubMed
    Score: 0.354
  8. Distribution of IgM and IgG antibodies to oxidized LDL in immune complexes isolated from patients with type 1 diabetes and its relationship with nephropathy. Clin Immunol. 2008 Jun; 127(3):394-400.
    View in: PubMed
    Score: 0.332
  9. Atherogenesis and the humoral immune response to modified lipoproteins. Atherosclerosis. 2008 Oct; 200(2):239-46.
    View in: PubMed
    Score: 0.329
  10. The immunogenicity of modified lipoproteins. Ann N Y Acad Sci. 2005 Jun; 1043:367-78.
    View in: PubMed
    Score: 0.270
  11. Development of capture assays for different modifications of human low-density lipoprotein. Clin Diagn Lab Immunol. 2005 Jan; 12(1):68-75.
    View in: PubMed
    Score: 0.262
  12. Definition of the immunogenic forms of modified human LDL recognized by human autoantibodies and by rabbit hyperimmune antibodies. J Lipid Res. 2004 Oct; 45(10):1859-67.
    View in: PubMed
    Score: 0.254
  13. Role of simvastatin as an immunomodulator in type 2 diabetes. Diabetes Care. 2004 Apr; 27(4):908-13.
    View in: PubMed
    Score: 0.249
  14. The role of immune and inflammatory processes in the development of macrovascular disease in diabetes. Front Biosci. 2003 Sep 01; 8:s750-68.
    View in: PubMed
    Score: 0.239
  15. Lipoprotein autoantibodies: measurement and significance. Clin Diagn Lab Immunol. 2003 Jul; 10(4):499-505.
    View in: PubMed
    Score: 0.236
  16. Humoral immunity and atherosclerosis. Nat Med. 2003 Mar; 9(3):243-4; author reply 244-5.
    View in: PubMed
    Score: 0.231
  17. Immune Complexes and the Risk of CVD in Type 1 Diabetes. Diabetes. 2019 09; 68(9):1853-1860.
    View in: PubMed
    Score: 0.179
  18. Glycosylated sphingolipids and progression to kidney dysfunction in type 1 diabetes. J Clin Lipidol. 2019 May - Jun; 13(3):481-491.e1.
    View in: PubMed
    Score: 0.176
  19. F(ab')2 fragments of anti-oxidized LDL IgG attenuate vascular inflammation and atherogenesis in diabetic LDL receptor-deficient mice. Clin Immunol. 2016 Dec; 173:50-56.
    View in: PubMed
    Score: 0.146
  20. High levels of AGE-LDL, and of IgG antibodies reacting with MDA-lysine epitopes expressed by oxLDL and MDA-LDL in circulating immune complexes predict macroalbuminuria in patients with type 2 diabetes. J Diabetes Complications. 2016 May-Jun; 30(4):693-9.
    View in: PubMed
    Score: 0.141
  21. Response to comment on Lopes-Virella et al. Baseline markers of inflammation are associated with progression to macroalbuminuria in type 1 diabetic subjects. Diabetes care 2013;36:2317-2323. Diabetes Care. 2014 May; 37(5):e108-9.
    View in: PubMed
    Score: 0.123
  22. Baseline markers of inflammation are associated with progression to macroalbuminuria in type 1 diabetic subjects. Diabetes Care. 2013 Aug; 36(8):2317-23.
    View in: PubMed
    Score: 0.116
  23. The levels of MDA-LDL in circulating immune complexes predict myocardial infarction in the VADT study. Atherosclerosis. 2012 Oct; 224(2):526-31.
    View in: PubMed
    Score: 0.111
  24. Enhanced uptake and impaired intracellular metabolism of low density lipoprotein complexed with anti-low density lipoprotein antibodies. Arterioscler Thromb. 1991 Sep-Oct; 11(5):1356-67.
    View in: PubMed
    Score: 0.104
  25. Oxidized LDL immune complexes stimulate collagen IV production in mesangial cells via Fc gamma receptors I and III. Clin Immunol. 2011 Jun; 139(3):258-66.
    View in: PubMed
    Score: 0.100
  26. Risk factors related to inflammation and endothelial dysfunction in the DCCT/EDIC cohort and their relationship with nephropathy and macrovascular complications. Diabetes Care. 2008 Oct; 31(10):2006-12.
    View in: PubMed
    Score: 0.084
  27. Oxidized LDL immune complexes and oxidized LDL differentially affect the expression of genes involved with inflammation and survival in human U937 monocytic cells. Atherosclerosis. 2009 Feb; 202(2):394-404.
    View in: PubMed
    Score: 0.083
  28. OxLDL immune complexes activate complement and induce cytokine production by MonoMac 6 cells and human macrophages. J Lipid Res. 2006 Sep; 47(9):1975-83.
    View in: PubMed
    Score: 0.073
  29. Immune complexes containing modified lipoproteins are related to the progression of internal carotid intima-media thickness in patients with type 1 diabetes. Atherosclerosis. 2007 Feb; 190(2):359-69.
    View in: PubMed
    Score: 0.071
  30. LDL immune complexes stimulate LDL receptor expression in U937 histiocytes via extracellular signal-regulated kinase and AP-1. J Lipid Res. 2003 Jul; 44(7):1315-21.
    View in: PubMed
    Score: 0.058
  31. Autoimmune response to advanced glycosylation end-products of human LDL. J Lipid Res. 2003 Mar; 44(3):487-93.
    View in: PubMed
    Score: 0.057
  32. Chlamydophila pneumoniae infection of human aortic endothelial cells induces the expression of FC gamma receptor II (FcgammaRII). Clin Immunol. 2002 Sep; 104(3):265-73.
    View in: PubMed
    Score: 0.056
  33. Anti-modified LDL antibodies, LDL-containing immune complexes, and susceptibility of LDL to in vitro oxidation in patients with type 2 diabetes. Diabetes. 2000 Jun; 49(6):1033-41.
    View in: PubMed
    Score: 0.048
  34. Association Between Inflammatory Markers and Progression to Kidney Dysfunction: Examining Different Assessment Windows in Patients With Type 1 Diabetes. Diabetes Care. 2018 01; 41(1):128-135.
    View in: PubMed
    Score: 0.040
  35. Longitudinal Association Between Endothelial Dysfunction, Inflammation, and Clotting Biomarkers With Subclinical Atherosclerosis in Type 1 Diabetes: An Evaluation of the DCCT/EDIC Cohort. Diabetes Care. 2015 Jul; 38(7):1281-9.
    View in: PubMed
    Score: 0.033
  36. The predictive role of markers of Inflammation and endothelial dysfunction on the course of diabetic retinopathy in type 1 diabetes. J Diabetes Complications. 2015 Jan-Feb; 29(1):108-14.
    View in: PubMed
    Score: 0.032
  37. Decreased plasma levels of select very long chain ceramide species are associated with the development of nephropathy in type 1 diabetes. Metabolism. 2014 Oct; 63(10):1287-95.
    View in: PubMed
    Score: 0.032
  38. Immune complex formation in human diabetic retina enhances toxicity of oxidized LDL towards retinal capillary pericytes. J Lipid Res. 2014 May; 55(5):860-9.
    View in: PubMed
    Score: 0.031
  39. Oxidized LDL and AGE-LDL in circulating immune complexes strongly predict progression of carotid artery IMT in type 1 diabetes. Atherosclerosis. 2013 Dec; 231(2):315-22.
    View in: PubMed
    Score: 0.030
  40. Differential regulation of acid sphingomyelinase in macrophages stimulated with oxidized low-density lipoprotein (LDL) and oxidized LDL immune complexes: role in phagocytosis and cytokine release. Immunology. 2012 May; 136(1):30-45.
    View in: PubMed
    Score: 0.027
  41. High concentrations of AGE-LDL and oxidized LDL in circulating immune complexes are associated with progression of retinopathy in type 1 diabetes. Diabetes Care. 2012 Jun; 35(6):1333-40.
    View in: PubMed
    Score: 0.027
  42. High levels of oxidized LDL in circulating immune complexes are associated with increased odds of developing abnormal albuminuria in Type 1 diabetes. Nephrol Dial Transplant. 2012 Apr; 27(4):1416-23.
    View in: PubMed
    Score: 0.026
  43. Erythrocyte-bound low-density lipoprotein immune complexes lead to cholesteryl ester accumulation in human monocyte-derived macrophages. Clin Immunol Immunopathol. 1991 Apr; 59(1):37-52.
    View in: PubMed
    Score: 0.025
  44. Differential trafficking of oxidized LDL and oxidized LDL immune complexes in macrophages: impact on oxidative stress. PLoS One. 2010 Sep 02; 5(9).
    View in: PubMed
    Score: 0.024
  45. LDL-containing immune complexes in the DCCT/EDIC cohort: associations with lipoprotein subclasses. J Diabetes Complications. 2011 Mar-Apr; 25(2):73-82.
    View in: PubMed
    Score: 0.024
  46. Heat shock protein 70B' (HSP70B') expression and release in response to human oxidized low density lipoprotein immune complexes in macrophages. J Biol Chem. 2010 May 21; 285(21):15985-93.
    View in: PubMed
    Score: 0.024
  47. Low density lipoprotein metabolism by human macrophages activated with low density lipoprotein immune complexes. A possible mechanism of foam cell formation. J Exp Med. 1988 Sep 01; 168(3):1041-59.
    View in: PubMed
    Score: 0.021
  48. Novel predictors of overt nephropathy in subjects with type 1 diabetes. A nested case control study from the Pittsburgh Epidemiology of Diabetes Complications cohort. Nephrol Dial Transplant. 2006 Jan; 21(1):93-100.
    View in: PubMed
    Score: 0.017
  49. Markers of endothelial dysfunction in the prediction of coronary artery disease in type 1 diabetes. The Pittsburgh Epidemiology of Diabetes Complications Study. J Diabetes Complications. 2005 Jul-Aug; 19(4):183-93.
    View in: PubMed
    Score: 0.017
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.